Navigation Links
Pfenex Reports Second Quarter 2014 Results and Provides Business Update
Date:8/29/2014

t June 30, 2014 and December 31, 2013, respectively; 3,556,186 shares issued andoutstanding; $13,815,111 liquidation preference49,40049,200Redeemable convertible Series A-1 preferred stock, par value $0.001,5,000,000 and 4,978,662 shares authorized at June 30, 2014 and December 31, 2013, respectively;, 4,978,661 shares issued andoutstanding; $16,470,071 liquidation preference64,54063,980Stockholders' equity (deficit):Common stock, $.001 par value, 30,000,000 and 12,514,224 shares authorized at June 30, 2014 and December 31, 2013, respectively; 1,571,473 and 1,541,781 shares issued and outstanding at June 30, 2014 and December 31, 2013, respectively42Additional paid-in capital--Accumulated deficit(98,847)(94,453)Total stockholders' equity (deficit)(98,843)(94,451)Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)$
29,088
$
31,813
Note: The Pfenex Condensed Statement of Operations and Balance Sheet for the period ended June 30, 2014 does not reflect the Pfenex initial public offering that closed on July 29, 2014. 

Logo - http://photos.prnewswire.com/prnh/20140715/127348


'/>"/>
SOURCE Pfenex Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Pfenex Inc. Awards Glide Pharma Development Contract for a Solid Formulation of Recombinant Anthrax Vaccine
2. Pfenex Inc. Awards Paragon Bioservices a Contract for cGMP Manufacturing of its Recombinant Protective Antigen (rPA), for Phase 1 Clinical Trial of its Anthrax Vaccine
3. Pfenex Awarded Contract For Development Of Next Generation rPA-Based Anthrax Vaccine
4. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
5. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
6. Interleukin Genetics Reports Third Quarter 2011 Financial Results
7. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
8. Nile Therapeutics Reports 2011 Third Quarter Financial Results
9. Pharmasset Reports Fiscal Year End 2011 Financial Results
10. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
11. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014   Synthetic Biologics, ... novel pathogen-specific therapies for serious infections and diseases, announced ... issued a Notice of Allowance for a composition of ... C. difficile program, SYN-004. This is Synthetic ... in the U.S. and adds to the Company,s extensive ...
(Date:10/22/2014)... -- Nuvilex, Inc. (OTCQB: NVLX) – According to the ... living with diabetes, with  that number expected to grow ... for diabetes treatments is approximately $500 billion.  ... pancreatic cancer.  Pancreatic cancer is the fourth most common ... the United States , and according to a ...
(Date:10/22/2014)... and HONG KONG , Oct. 22, ... therapeutics enterprise, announced today that rare disease expert ... vice president, research. Dr. McKew brings more than two ... positions at the National Institutes of Health, Wyeth Research ... Wyeth). Dr. McKew will lead aTyr,s efforts to expand and ...
(Date:10/20/2014)... Oct. 20, 2014 Mapp Biopharmaceutical,s valiant ... antibody therapeutic to fight the Ebola outbreak will ... time-consuming the production of pharmaceuticals can be, according ... said that while some may be taken aback ... those with industry knowledge are well aware of ...
Breaking Biology Technology:Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3
... Web addicts, take heart: A public-private effort is moving ... , AOL-SkyCable has been chosen to enter negotiations ... for the general public. The "Wireless Wisconsin" service would ... Madison and the Dane County Regional Airport. The project ...
... Information-technology businesses are taking apart their processes ... 2005 CEO-CIO Symposium on Wednesday just around the ... offered their opinions on how the state and its ... year progresses. , Restructuring and rebuilding ,According to ...
... Johnson Controls Inc. has completed ... a French company, Valeo. Valeo is based in ... million) for the business, headquartered in Pontoise, France, ... engines. Johnson Controls bought the division from another ...
Cached Biology Technology:Madison wi-fi plans move ahead 2Restructuring is a watchword for IT in 2005 2Restructuring is a watchword for IT in 2005 3
(Date:10/22/2014)... 20, 2014 The Nano-Bio Manufacturing Consortium (NBMC), ... Research Laboratory (AFRL), has chosen a project proposed by ... University of Arizona College of Medicine – ... project,s goal is to assess different sweat collection methods ... of sweat under a variety of human-body conditions, the ...
(Date:10/18/2014)... patients referred for evaluation of suspected genetic conditions, ... 25 percent, including detection of a number of ... disease, according to a study appearing in ... coincide with the American Society of Human Genetics ... or coding regions of thousands of genes simultaneously ...
(Date:10/17/2014)... To date, antidotes ... doctors are often limited to supportive therapy such as induced ... of drugs involved. So what can be done if a ... professor Jean-Christophe Leroux from the Institute of Pharmaceutical Sciences at ... "The task was to develop an agent that could eliminate ...
Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 2Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 3Whole-exome sequencing shows potential as diagnostic tool 2Emergency aid for overdoses 2Emergency aid for overdoses 3
... SAN FRANCISCO An increasing number of obese adolescents, ... case study presented Sunday, Oct. 3, at the American ... San Francisco, highlights the possible link between gastric bypass ... neural tube defects, which can lead to varying degrees ...
... of private health insurance and its consequent lack of ... with uterine cancer and may partly explain the mortality ... data presented at the Third AACR Conference on The ... twice as likely to die within four years compared ...
... breast cancer that lacked estrogen and progesterone receptors and did ... those with other types of invasive breast cancer, according to ... Science of Cancer Health Disparities, held Sept. 30 Oct. ... in Puerto Rico, following U.S. trends, it is important to ...
Cached Biology News:Loss of nutrients following gastric bypass surgery in adolescent girls 2Lack of private health insurance impacted cancer survival 2Decreased survival for Puerto Rican women with 'triple-negative' breast cancer subtype 2
Mouse monoclonal [1241] to Parainfluenza Virus type 2...
Mouse monoclonal [0.N.509] to PCTAIRE2 ( Abpromise for all tested applications). entrezGeneID: 5128 SwissProtID: Q00537...
Parathyroid Hormone Receptor 2 [PTHR2]...
... the caudal-related homeobox family, is an intestine-specific ... differentiation in intestinal epithelial cells. It plays ... the phenotype of differentiated villus enterocytes as ... phenotype. Clone CDX2-88 reacts with a conserved ...
Biology Products: